N4 Pharma AGM to be held on 24 March 2022

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, are now available on the Company’s website www.n4pharma.com and will be posted to shareholders today.

The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma updates on Nuvec AAV Viral Vector research

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing research work into the use of Nuvec® to enhance the

    N4 Pharma

    N4 Pharma plc Nuvec Oral Delivery Update

    N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery research work. The Company through its research program with

    N4 Pharma

    N4 Pharma plc Nuvec® R&D and Strategy Update

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The Company’s double loaded siRNA work is ongoing and

    N4 Pharma

    N4 Pharma launch Interactive Investor Hub

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders, the new

    N4 Pharma

    N4 Pharma updated investor presentation

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis Limited is

    N4 Pharma

    N4 Pharma acquires of a controlling interest in Nanogenics

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company

    N4 Pharma

    N4 Pharma granting of patent application in the United States

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The University of Queensland has informed the Company that it has

    N4 Pharma

    N4 Pharma updates on in vitro results for Nuvec®

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further to the

    N4 Pharma

    N4 Pharma Nuvec well suited for working with siRNA

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The Company has completed the single loading of both

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a delivery system

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its

    N4 Pharma

    N4 Pharma greatly encouraged by the oral delivery of Nuvec results

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced today to

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary shares of

    No more posts to show